The Rush to Comparative Effectiveness: FDA's Woodcock Hopes It Won't Overshadow Personalized Medicine

Comparative effectiveness research is a central theme of the Obama Administration's health reform effort. But as the debate heats up on Capitol Hill, one top FDA official, Janet Woodcock, doesn't want to lose sight of an increasingly important drug development strategy: personalized medicine.